Yuanzhong Wu

17PUBLICATIONS
51CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 23, 2026
DTX3 promotes anti-tumor immunity by inducing PD-L1 ubiquitination and is suppressed by p65/miR-222 in bladder cancer.

|Jul 16, 2026
Author Correction: Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.

|Jul 01, 2026
Reconsidering Cancer Therapy through the Lens of Biomolecular Condensates.

|May 29, 2025
ASB7 is a negative regulator of H3K9me3 homeostasis.

Liwen Zhou, Zhenxuan Chen, Yezi Zou

|Apr 29, 2025
The assembly of RAB22A/TMEM33/RTN4 initiates a secretory ER-phagy pathway.

Xueping Zheng, Dongmei Fang, Hao Shan

|Apr 21, 2025
Lysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1.

Xiaobo He, Qiu-Xia Wang, Denghui Wei

Pageof 3

Frequent Collaborators

10 joint publications

Tiebang Kang

4 joint publications

Ying Gao

3 joint publications

Denghui Wei

3 joint publications

Xiaodan Huang